Editas Medicine (EDIT) 2024 Wells Fargo Healthcare Conference summary

Strategic pillars and platform overview

• Focused on autologous ex vivo cell therapy for sickle cell disease and thalassemia, evolving in vivo editing pipeline, and leveraging foundational IP for non-dilutive financing.

• Reni-cel program shows strong progress, with over 20 patients dosed and completed enrollment in registration studies.

• In vivo proof of concept targeted by year-end, aiming for first- or best-in-class therapeutics via functional upregulation.

• IP estate validated by recent Vertex deal, supporting cash runway and licensing opportunities.

• Cash runway extends into 2026, with ongoing partnerships such as the expanded BMS T cell agreement.

Clinical data and product differentiation

• Reni-cel demonstrates 100% of patients achieving >40% fetal hemoglobin at six months, with mean around 45%.

• Sustained correction of anemia and rapid neutrophil engraftment (23 days) observed, potentially faster than competitors.

• High manufacturing success rates and favorable safety profile, with no editing-related adverse events.

• Differentiation from CASGEVY includes higher hemoglobin normalization and faster engraftment, valued by clinicians and hospitals.

• Shorter engraftment time benefits both patient recovery and hospital profitability.

Market outlook and adoption

• Sickle cell market expected to grow, with increasing patient and physician awareness and improved contracting timelines.

• Medicaid and federal initiatives are streamlining reimbursement and access, with pilot programs launching in 2025.

• Observing and leveraging market developments to accelerate future product launches.

• Infertility risk is attributed to conditioning, not gene editing; fertility preservation practices are being optimized.

• Ongoing legal and policy efforts to secure fertility preservation coverage for patients.